3.28
2.82%
+0.0900
(Pre-market:
.00
-3.28
-100.00%)
Allakos Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Allakos Inc. was founded in 2012 and is headquartered in San Carlos, California.
List of SPAC Stocks
List of EV Stocks and Related Stocks
Top 100 popular stocks on Robinhood
List of Marijuana Stocks
Cap:
|
Volume (24h):